Business Context and Reporting Period
This Form 8-K Current Report was filed by AntriaBio, Inc. on October 9, 2017. The report discloses a corporate governance event: the appointment of a new member to the Board of Directors. Note: The request metadata references "Rezolute, Inc.," but the filing text explicitly identifies the registrant as AntriaBio, Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to the disclosure of a board appointment and related regulatory notices.
Material Changes
The material change reported is the appointment of Gil Labrucherie to the Board of Directors, effective October 5, 2017. Mr. Labrucherie will serve on the Nominating and Governance Committee, the Audit Committee, and the Compensation Committee. He is classified as an independent director under NASDAQ rules.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business performance. It includes a standard Regulation FD disclosure stating that the press release information is "furnished" rather than "filed" and does not constitute an admission of materiality for purposes of the Securities Exchange Act of 1934. No specific risks or contingencies are detailed in this report.
Investor Verification Checklist
- Verify the registrant name is AntriaBio, Inc., not Rezolute, Inc.
- Confirm Gil Labrucherie's current role as CFO of Nektar Therapeutics and his prior tenure as SVP, General Counsel, and Secretary.
- Review the attached press release (Exhibit 99.1) for any additional context on the appointment.
- Check subsequent filings for any compensation agreements, as this report states none were entered into at the time of appointment.